天芪降糖胶囊治疗新诊断2型糖尿病的血糖达标率与安全性分析

Key Points

• To investigate the efficacy and safety of Tianqi reducing sugar capsules combined with metformin in newly diagnosed type 2 diabetes patients.
• 118 newly diagnosed type 2 diabetes patients were randomly assigned to metformin or combination therapy.
• Patients' fasting blood glucose, postprandial blood glucose, and glycated hemoglobin were measured.
• Comparative analysis included evaluating blood glucose control rates and adverse reactions.
• Both groups showed reduced fasting blood glucose, postprandial blood glucose, and glycated hemoglobin levels.
• The combination therapy group exhibited significantly lower levels compared to the metformin group.
• The combination therapy had a higher blood glucose control rate than metformin alone.
• No serious adverse reactions were reported in either group.